Cargando…
Influenza Virus Sialidase - A Drug Discovery Target
Influenza continues to be an ongoing problem despite the existence of vaccines and drugs. Disease outbreaks can occur relatively quickly as witnessed with the recent emergence of the influenza virus A/H1N1 pandemic. The development of new anti-influenza drugs is thus a major challenge. This volume d...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Basel :
Springer Basel : Imprint: Springer,
2012.
|
| Edición: | 1st ed. 2012. |
| Colección: | Milestones in Drug Therapy,
|
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-7643-8927-7 | ||
| 003 | DE-He213 | ||
| 005 | 20220117183202.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 110830s2012 sz | s |||| 0|eng d | ||
| 020 | |a 9783764389277 |9 978-3-7643-8927-7 | ||
| 024 | 7 | |a 10.1007/978-3-7643-8927-7 |2 doi | |
| 050 | 4 | |a RM300-666 | |
| 072 | 7 | |a MMG |2 bicssc | |
| 072 | 7 | |a MED071000 |2 bisacsh | |
| 072 | 7 | |a MKG |2 thema | |
| 082 | 0 | 4 | |a 615 |2 23 |
| 245 | 1 | 0 | |a Influenza Virus Sialidase - A Drug Discovery Target |h [electronic resource] / |c edited by Mark Itzstein. |
| 250 | |a 1st ed. 2012. | ||
| 264 | 1 | |a Basel : |b Springer Basel : |b Imprint: Springer, |c 2012. | |
| 300 | |a IX, 178 p. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Milestones in Drug Therapy, |x 2296-6064 | |
| 505 | 0 | |a Influenza Virus Virology -- Investigating the interaction between influenza and sialic acid - making and breaking the link -- Enzymology of Influenza Virus Sialidase -- Influenza Virus Sialidase and Structure-Based Drug Design -- The Development of Carbohydrate-based Influenza Virus Sialidase Inhibitors -- The Development of Non-carbohydrate-based Influenza Virus Sialidase Inhibitors -- Clinical Experience with Influenza Virus Sialidase Inhibitors -- Resistance Development to Influenza Virus Sialidase Inhibitors. | |
| 520 | |a Influenza continues to be an ongoing problem despite the existence of vaccines and drugs. Disease outbreaks can occur relatively quickly as witnessed with the recent emergence of the influenza virus A/H1N1 pandemic. The development of new anti-influenza drugs is thus a major challenge. This volume describes all aspects of the virus structure and function relevant to infection. The focus is on drug discovery of inhibitors to the enzyme sialidase, which plays a key role in the infectious lifecycle of the virus. Following an overview of the influenza virus, the haemagglutinin, the interactions with the cell receptors and the enzymology of virus sialidase, recent results in drug design are presented. These include a full coverage of the design, synthesis and evaluation of carbohydrate as well as non-carbohydrate influenza virus sialidase inhibitors. Further reviews of the clinical experience with influenza virus sialidase inhibitors and of the development of resistance to these inhibitor drugs complement the topic. | ||
| 650 | 0 | |a Pharmacology. | |
| 650 | 0 | |a Diseases. | |
| 650 | 0 | |a Virology. | |
| 650 | 0 | |a Immunology. | |
| 650 | 1 | 4 | |a Pharmacology. |
| 650 | 2 | 4 | |a Diseases. |
| 650 | 2 | 4 | |a Virology. |
| 650 | 2 | 4 | |a Immunology. |
| 700 | 1 | |a Itzstein, Mark. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783764389307 |
| 776 | 0 | 8 | |i Printed edition: |z 9783764389260 |
| 776 | 0 | 8 | |i Printed edition: |z 9783034807791 |
| 830 | 0 | |a Milestones in Drug Therapy, |x 2296-6064 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-3-7643-8927-7 |z Texto Completo |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||